Table III.
Association between the expression of miR-551b-3p and clinicopathological characteristics of gastric cancer.
| Variable | Cases, n (%) | Expression of miR-551b-3p, median ± range | P-value |
|---|---|---|---|
| Gender | 0.857 | ||
| Male | 32 (57) | 8.684±0.417 | |
| Female | 24 (43) | 8.798±0.470 | |
| Age, years | 0.785 | ||
| ≤50 | 18 (32) | 8.857±0.362 | |
| >50 | 38 (68) | 8.674±0.425 | |
| Tumor size, cm | 0.360 | ||
| ≤5 | 31 (55) | 8.475±0.445 | |
| >5 | 25 (45) | 9.052±0.420 | |
| Degree of differentiation | 0.015* | ||
| Well and moderately | 17 (30) | 7.148±0.601 | |
| Poorly | 39 (70) | 9.988±0.356 | |
| TNM stage | 0. 039* | ||
| I/II | 27 (48) | 5.902±0.436 | |
| III/IV | 29 (52) | 8.575±0.442 | |
| Lymph-node status | 0.013* | ||
| No metastasis | 6 (11) | 8.470±0.310 | |
| Metastasis | 50 (89) | 10.924±0.937 |
miR, microRNA; TNM, tumor node metastasis.